What topline oncology press releases leave out: a methodological case study of the MonumenTAL-6 announcement (teclistamab plus talquetamab, relapsed/refractory multiple myeloma)

On July 23, 2026, Johnson & Johnson announced topline results from the phase 3 MonumenTAL-6 trial, reporting that teclistamab plus talquetamab (Tec-Tal) reduced the risk of progression or death by 89% (hazard ratio [HR] 0.11, 95% CI 0.08-0.16, p<0.0001) and the risk of death by 62% (HR 0.38) versus investigator's choice of standard-of-care regimens in relapsed/refractory multiple myeloma. No published trial report yet exists; full results are reserved for a future medical meeting. This commentary does not evaluate whether the treatment effect is real - the trial is randomized, its primary endpoint is assessed by an independent review committee, and the reported p-value is clear. Instead, it applies established methodological literature on early-stopped trials, indirect treatment comparisons, and press-release reporting to identify four specific, checkable gaps in what was disclosed: (1) no absolute event rates, medians, or event counts were reported alongside the hazard ratios; (2) the Independent Data Monitoring Committee unblinded the study at its first interim analysis without disclosing the event count, interim-analysis plan, or stopping boundary; (3) the release calls the result "the lowest hazard ratio seen across any Phase 3 study" of bispecific therapies in this disease, but topline HRs from trials with different control-arm compositions cannot establish a comparative ranking without a formal indirect analysis; (4) the release states only that safety was "consistent with the known safety profiles of each monotherapy," without a single combination-specific figure, while historical data on the same two-drug combination document a substantial infection burden and contain non-identical summary estimates whose relationship is not explained in the source poster. None of these observations implies data fabrication or misconduct; each specifies information needed before a stopped-early, unpublished result can be independently evaluated as a public efficacy and safety claim.